Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$26.39M
Current Assets
2025 Q4
$9.866M
Current Liabilities
2025 Q4
$7.753M
Current Ratio
2025 Q4
127.25%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
$7.858M
Book Value
2025 Q4
$9.714M
Cash
2025 Q4
$8.717M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$2.616M

Stock Price

Loading...
Market Cap: $20.261 Million

About Purple Biotech Ltd

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 10 full-time employees. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Industry: Pharmaceutical Preparations Peers: Mediwound Ltd Sol Gel Technologies Ltd TARO PHARMACEUTICAL INDUSTRIES LTD

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support